RPA-CRISPR / Cas12a-based crRNA for detecting common respiratory viruses, multiple detection kit and application

By combining RPA-CRISPR/Cas12a technology and specific crRNA/RPA amplification primers, the false negative problem of respiratory virus detection in the prior art is solved, and high sensitivity, rapid and accurate detection of multiple viruses is achieved, suitable for complex Pathogens are mixed infecting the environment.

CN118996006APending Publication Date: 2024-11-22HEFEI INSTITUTE OF PHYSICAL SCIENCE CHINESE ACADEMY OF SCIENCES
View PDF 0 Cites 8 Cited by

Patent Information

Application Number
CN202411236298.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art has false negative problems when detecting respiratory viruses, especially because the frequency of viral gene mutations is high, and conventional PCR or isothermal amplification methods are prone to introduce base mismatch, resulting in inaccurate detection results, and mixed infection of multiple pathogens aggravate the symptoms. , difficult to accurately diagnose.

Method used

Using RPA-CRISPR/Cas12a detection method, combining crRNA and RPA amplification primers, using CRISPR-Cas12a system and recombinant polymerase isothermal amplification technology to improve the reliability and sensitivity of diagnostic results, and design specific crRNA and RPA amplification Primer sequences are used to detect novel coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus and parainfluenza virus.

Benefits of technology

It improves the reliability and sensitivity of diagnostic results, can detect multiple respiratory viruses in a short time, reduces the false negative rate, is suitable for rapidly distinguishing multiple respiratory pathogens, and enhances the specific recognition ability of pathogens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118996006A_ABST
    Figure CN118996006A_ABST
Patent Text Reader

Abstract

The invention discloses crRNA for detecting common respiratory viruses based on RPA-CRISPR / Cas12a, a multiple detection kit and application, and relates to the technical field of respiratory virus detection. The crRNA sequence for detecting the novel coronavirus is as shown in SEQ ID NO: 1 or SEQ ID NO: 4; the crRNA sequence for detecting the influenza A virus is as shown in SEQ ID NO: 7; the crRNA sequence for detecting the influenza B virus is as shown in SEQ ID NO: 10; the crRNA sequence for detecting the respiratory syncytial virus is as shown in SEQ ID NO: 13; the crRNA sequence for detecting the parainfluenza virus is as shown in SEQ ID NO: 16. The method has the beneficial effects that a CRISPR-Cas system can be combined with a recombinant polymerase isothermal amplification technology, relatively high sensitivity and specificity are shown in the aspect of improving the reliability of a diagnosis result, and the number of detection targets can be increased by combining a centrifugal micro-fluidic chip.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of respiratory virus detection, and in particular to a common respiratory virus multiplex detection kit based on RPA--CRISPRCas12a and applications thereof. Background Art

[0002] The outbreak of the novel coronavirus (SARS-CoV-2) has had a devastating impact on global public health and has caused a significant socioeconomic burden. The symptoms caused by the novel coronavirus are very similar to the clinical symptoms of other common respiratory viral infections, such as fever, cough, and shortness of breath. During the COVID-19 pandemic, up to 30-71% of cases from different countries reported co-infection with SARS-CoV-2 and other respiratory viruses, including influenza A, influenza B, respiratory syncytial virus, and parainfluenza virus. All of the above viruses can cause upper and lower respiratory tract infections. Mixed infections with multiple pathogens can also aggravate the patient's clinical symptoms and endanger the patient's life. Doctors find it difficult to distinguish pathogens without reliable laboratory analysis. Therefore, accurate and rapid diagnosis of pathogens is of great significance for implementing appropriate antiviral treatment, saving lives, preventing epidemics, and reducing unnecessary use of antibiotics.

[0003] Due to the high frequency of viral gene mutation, conventional viral nucleic acid detection methods based on polymerase chain reaction (PCR) or isothermal amplification principles are prone to introduce base mismatches during the amplification process, resulting in the inability to accurately identify mutant genes, causing "false negative" test results. Clustered regularly interspaced short palindromic repeats (CRISPR) is an adaptive immune system in bacteria. The CRISPR-Cas system has become the fastest-growing and most widely used technology in the field of gene editing due to its high specificity, strong developability, simplicity, and efficiency.

[0004] The Chinese patent application document with publication number CN111534643A discloses a kit, detection method and application for detecting nucleic acids of respiratory pathogens, which includes a CRISPR-Cas detection system: crRNA, primer pairs, Cas protein and nucleic acid probe. The kit and detection method of this patent can be used to efficiently and quickly detect / diagnose respiratory pathogens (such as influenza A, influenza B and new coronavirus, etc.), with high specificity and sensitivity, and can be used for the detection and screening of respiratory pathogens, such as rapid differentiation of multiple respiratory pathogens including influenza A, influenza B and new coronavirus. However, the patent does not disclose the CrRNA sequence of the present invention. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide a crRNA for detecting respiratory viruses based on RPA-CRISPR / Cas12a and its application.

[0006] The present invention solves the above technical problems through the following technical means:

[0007] The first aspect of the present invention proposes a crRNA for detecting respiratory viruses based on RPA-CRISPR / Cas12a, wherein the respiratory viruses include one or more of the new coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus and / or parainfluenza virus; the crRNA sequence for detecting the new coronavirus is shown in SEQ ID NO: 1 or SEQ ID NO: 4; the crRNA sequence for detecting influenza A virus is shown in SEQ ID NO: 7; the crRNA sequence for detecting influenza B virus is shown in SEQ ID NO: 10; the crRNA sequence for detecting respiratory syncytial virus is shown in SEQ ID NO: 13; the crRNA sequence for detecting parainfluenza virus is shown in SEQ ID NO: 16.

[0008] Beneficial effects: The crRNA in the present invention can be applied to the detection of respiratory viruses, and can combine the CRISPR-Cas12a system with the recombinase polymerase isothermal amplification (RPA) technology, showing high sensitivity in improving the reliability of diagnostic results, and has certain advantages in increasing the number of detection targets and reducing detection time.

[0009] The second aspect of the present invention proposes RPA amplification primers for amplifying respiratory viruses based on the above-mentioned crRNA, and the sequences of the RPA amplification primers for amplifying the new coronavirus are shown in SEQ ID NOs: 2-3 or SEQ ID NOs: 5-6; the sequences of the RPA amplification primers for amplifying influenza A virus are shown in SEQ ID NOs: 8-9; the sequences of the RPA amplification primers for amplifying influenza B virus are shown in SEQ ID NOs: 11-12; the sequences of the RPA amplification primers for amplifying respiratory syncytial virus are shown in SEQ ID NOs: 14-15; the sequences of the RPA amplification primers for amplifying parainfluenza virus are shown in SEQ ID NOs: 17-18.

[0010] Wherein SEQ ID NO:2-3 means SEQ ID NO:2 and SEQ ID NO:3, and the others are similar.

[0011] Beneficial effects: The RPA amplification primers in the present invention can be applied to the detection of respiratory viruses, and can combine the CRISPR-Cas system with the recombinase isothermal amplification recombinase polymerase amplification (RPA) technology, showing ultra-high sensitivity and specificity in improving the reliability of diagnostic results.

[0012] The preparation method of RPA primers includes: designing RPA upstream and downstream primers on both sides of the crRNA target sequences of five common respiratory viruses and internal quality control genes that have been identified, using Oligo7 to design multiple pairs of conservative RPA primers, and screening out the optimal primer combination through real-time fluorescence curves and endpoint fluorescence values.

[0013] The third aspect of the present invention proposes a kit for detecting respiratory viruses based on RPA-CRISPR / Cas12a, the kit comprising the above-mentioned RPA amplification primers and CRISPR / Cas12a detection system; the CRISPR / Cas12a detection system includes the above-mentioned crRNA sequence, CRISPR / Cas12a protein and ssDNA reporter fluorescent probe.

[0014] Beneficial effects: The present invention combines the CRISPR-Cas system with the recombinase isothermal amplification (RPA) technology and applies it to the detection of common respiratory viruses, showing high sensitivity in improving the reliability of diagnostic results.

[0015] Preferably, the ssDNA reporter fluorescent probe is ssDNA labeled with 6-carboxyl fluorescence (6-FAM) and a fluorescence quencher (BHQ1).

[0016] Preferably, the sequence of the ssDNA reporter fluorescent probe is FAM-TTATT-BHQ1.

[0017] The fourth aspect of the present invention provides a method for detecting respiratory viruses using the above kit for non-disease diagnosis purposes, comprising the following steps:

[0018] (1) extracting nucleic acid from the sample to be tested;

[0019] (2) amplifying the nucleic acid in the sample to be tested using RPA amplification primers;

[0020] (3) After cutting the amplified product using the CRISPR / Cas12a detection system, the fluorescence signal is detected using a fluorescence detector to determine whether the sample contains respiratory viruses.

[0021] Beneficial effects: The present invention combines the CRISPR-Cas system with the recombinase isothermal amplification (RPA) technology and applies it to the detection of common respiratory viruses. It shows high sensitivity in improving the reliability of diagnostic results and adopts a self-developed centrifugal chip solution, which has certain advantages in the number of detection targets.

[0022] Preferably, the kit utilizes a centrifugal microfluidic chip or an EP tube for detection.

[0023] Preferably, when the kit uses a centrifugal microfluidic chip, the RPA amplification primers and crRNA sequences are pre-embedded in the chip reaction chamber in the form of freeze-dried powder, and the CRISPR / Cas12a detection system is pre-embedded in the chip independent detection chamber. The nucleic acid extracted in step (1) is added to the liquid reservoir, and the nucleic acid extracted in step (1) is diverted to the chip reaction chamber by centrifugation to perform RPA amplification reaction. After the amplification is completed, centrifugation is performed, and the amplification product enters the chip independent detection chamber. Finally, the fluorescence signal of the independent detection chamber is detected. When the independent detection chamber emits fluorescence, it indicates that the sample to be tested contains respiratory viruses. When the independent detection chamber does not emit fluorescence, it indicates that the sample to be tested is not infected with respiratory viruses.

[0024] Preferably, when the kit uses an EP tube, the CRISPR / Cas12a detection system is dripped into the inner wall of the EP tube cap, the RPA amplification primer is added to the bottom of the EP tube, and the sample to be tested is added to the bottom of the EP tube. After the amplification reaction is completed, the CRISPR / Cas12a detection system and the RPA amplification product are mixed by centrifugation to perform a detection reaction, and finally the fluorescence signal of the reaction system is detected. When the reaction system emits fluorescence, it indicates that the sample to be tested contains respiratory viruses. When the reaction system does not emit fluorescence, it indicates that the sample to be tested is not infected with respiratory viruses.

[0025] Preferably, in step (2), the concentration of the RPA amplification primer is 10 μM, and the concentration ratio of the upstream and downstream primers is 1:1.

[0026] Preferably, in step (2), an isothermal amplification system is used to amplify the specific product at 42° C. for 10 min.

[0027] Preferably, in the step (3) CRISPR / Cas12a detection system, the concentration of the crRNA sequence is 2 μM, the concentration of the ssDNA reporter fluorescent probe is 10 μM, and the concentration of Cas12a is 1 μM.

[0028] Preferably, the crRNA preparation method comprises the following steps: for the conserved sequences of five common respiratory viruses and internal quality control genes of novel coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus and parainfluenza virus, a "TTTN" structure is searched in the middle of the conserved sequence as a PAM motif, thereby designing a crRNA with a length of 18-24 nt; wherein, the crRNA of Cas12a has the following sequence characteristics: 5′-UAAUUUCUACUAAGUGUAGAU-target specific sequence-3′, the first half of the sequence is a crRNA repeat sequence, and is the same for all Cas12a; the second half is a target-specific sequence, which is designed according to the target sequence, and the target-specific sequence length can be between 18-24 nt, but does not contain PAM (TTTN), and the PAM motif should be located at the 5' end of the targeted non-complementary DNA sequence. The designed crRNA is translated into a DNA fragment with a T7 promoter (T7-crRNA); at the same time, an oligonucleotide T7-ALL complementary to the promoter sequence is synthesized; two complementary oligonucleotides with promoter sequences (a short oligonucleotide and a long chain) can form an asymmetric hybrid chain through a simple annealing reaction, that is, part of the DNA template forms a double chain. Using the hybrid chain DNA as a template, the target crRNA can be transcribed through the T7 in vitro transcription system.

[0029] The advantages of the present invention are:

[0030] The present invention combines the CRISPR-Cas12a system with the recombinase polymerase isothermal amplification (RPA) technology and applies it to the detection of common respiratory viruses. It shows high sensitivity in improving the reliability of diagnostic results and has certain advantages in the number of detection targets and detection time. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 This is a diagram showing the optimization results of the FQ fluorescent reporter molecule in Example 2 of the present invention.

[0032] Figure 2 This is a sensitivity diagram of the RPA--CRISPR / Cas12a kit in Example 3 of the present invention for detecting five common respiratory viruses.

[0033] Figure 3 Schematic diagram of the process of detecting viral nucleic acid by the centrifugal microfluidic chip RPA--CRISPR / Cas12a method in Example 3 of the present invention.

[0034] Figure 4 This is a graph showing the results of simultaneously detecting five common respiratory viruses using the centrifugal microfluidic chip RPA-CRISPR / Cas12a method in Example 4 of the present invention.

[0035] Figure 5 Schematic diagram of the process of detecting viral nucleic acid using the single-tube RPA-CRISPR / Cas12a method in Example 5 of the present invention.

[0036] Figure 6 This is a graph showing the results of detecting respiratory syncytial virus using the single-tube RPA-CRISPR / Cas12a method in Example 5 of the present invention. DETAILED DESCRIPTION

[0037] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0038] Unless otherwise specified, the test materials and reagents used in the following examples can be obtained from commercial sources.

[0039] If no specific techniques or conditions are specified in the examples, they can be carried out according to the techniques or conditions described in the literature in the art or according to the product instructions.

[0040] Embodiment 1:

[0041] Screening of crRNA of five common respiratory viruses and optimization of RPA primers

[0042] Targeting the conserved sequences of five common respiratory viruses and internal quality control genes, including the new coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus, and parainfluenza virus, the "TTTN" structure was searched in the middle of the conserved sequence as the PAM motif to design CrRNAs with a length of 18-24nt. Among them, the CrRNA of Cas12a has the following sequence characteristics: 5′-UAAUUUCUACUAAGUGUAGAU-target specific sequence-3′, the first half of the sequence is the CrRNA repeat sequence, and it is the same for all Cas12a; the second half is the target specific sequence, which is designed according to the target sequence.

[0043] The target-specific sequence length can be between 18-24nt, but does not contain PAM (TTTN). The PAM motif should be located at the 5' end of the non-complementary DNA sequence being targeted. The designed crRNA is translated into a DNA fragment with a T7 promoter (T7-crRNA); at the same time, an oligonucleotide T7-ALL complementary to the promoter sequence is synthesized; two complementary oligonucleotides with promoter sequences (a short oligonucleotide and a long chain) are annealed to form an asymmetric hybrid chain, that is, part of the DNA template forms a double strand. Using the hybrid chain DNA as a template, the target crRNA can be transcribed using the T7 in vitro transcription system.

[0044] The target is first amplified using the PCR amplification method, and then the CRISPR / Cas12a detection system is used to cut the amplified product on a real-time fluorescence PCR instrument. The reaction system is as follows:

[0045] PCR product 10μL, LbaCas12a 1μL, CrRNA 1μL, FQ Reporter 1μL, 10×NEBuffer 2μL. The reaction temperature was 42°C, and real-time fluorescence was collected every 30s. The optimal CrRNA was determined by the slope of the real-time fluorescence curve and the end-point fluorescence intensity. The CrRNA sequences of five common respiratory viruses and internal quality control genes are shown in Table 1.

[0046] Table 1: CrRNA sequences of five common respiratory viruses and internal quality control genes

[0047]

[0048]

[0049] Embodiment 2:

[0050] FQ Reporter is a single-stranded short DNA (ssDNA) with the fluorescent group FAM and the quenching group BHQ1 modified at both ends. When the fluorescent group and the quenching group are connected by DNA, no fluorescence will be emitted; when the ssDNA connecting the fluorescent group and the quenching group is cut by the Cas12a enzyme, the fluorescent group FAM emits fluorescence in the presence of the corresponding excitation light source, thereby displaying the result. Since FQ Reporter directly affects the fluorescence signal, the effect of the length of ssDNA on the fluorescence signal was explored. 5, 8, 11, and 14 nt ssDNA were selected as FQ Reporter for experiments, such as Figure 1 As shown, the fluorescence intensity increases with the increase of FQReporter length, but the background fluorescence also increases; when the Reporter length exceeds 8nt, the fluorescence intensity decreases, but the background fluorescence still increases. The present invention uses 5nt FQ Reporter to avoid the false positive problem caused by high background fluorescence.

[0051] Embodiment 3:

[0052] Sensitivity of RPA-CRISPR / Cas12a in detecting nucleic acids of five common respiratory viruses

[0053] In order to verify the sensitivity of the established RT / RPA-CRSPR system for virus detection, artificially prepared RNA was used as a template, and EASY Dilution was used to adjust the concentration and perform gradient dilutions so that the template concentrations of each group were 10 6 copies / μL, 10 5 copies / μL, 10 4 copies / μL, 10 3 copies / μL, 10 2 copies / μL, 10 1 Then, the virus RNA of each series of concentrations was used as a template, and the optimal CrRNA and the corresponding RPA primers were used to perform the corresponding RPA-CRSPR detection experiment on the LightCycler 96 fluorescence quantitative PCR instrument. The sensitivity was verified by the slope of the real-time fluorescence curve and the saturated fluorescence intensity. The sensitivity fluorescence curve of RT / RPA-CRSPR detection of SARS-CoV-2-1ab, SARS-CoV-2-N, IAV, IBV, HRSV, and HPIV3 is shown in the figure below. Figure 2 In this embodiment, the sensitivity of the RT / RPA-CRISPR detection system for detecting five respiratory viruses can reach 10 copies / μL, which is better than similar methods.

[0054] Embodiment 4:

[0055] Centrifugal microfluidic chip detects five common respiratory viruses simultaneously

[0056] Using a self-designed and manufactured centrifugal microfluidic chip, the new coronavirus standard, influenza A virus, influenza B virus, respiratory syncytial virus and parainfluenza virus quality control products were added to the human nasopharyngeal swab prepared in advance, mixed evenly and stored as simulated samples for later use. The simulated sample RNA was extracted using the Qiangen Mini kit as a template for chip detection. A 65μL loading mixture was prepared: 32.5μL of reconstitution solution (A buffer), 6.5μL of 10×NEB2.1, 8μL of magnesium acetate activator (B buffer), 10μL of sample template and 8μL of water.

[0057] like Figure 3 As shown, the sample mixture is injected into the chip with a pipette, and the chip is sealed with a cover sheet after the sample is added, and the detection experiment is carried out. The sealed chip is placed on a centrifuge and centrifuged at 3000rmp for 30s. The sample is distributed into the reaction chamber by centrifugation, and the RT / RPA reaction is carried out at 42°C for 10-15min. The chip is placed on the centrifuge again and centrifuged at 8000rmp for 30s. The amplified product is sent into the detection chamber by centrifugation, and the CRISPR reaction is carried out at 42°C for 10-15min. After the reaction, the end point fluorescence picture is collected.

[0058] like Figure 4 As shown, the test results of the simulated samples on the centrifugal microfluidic chip showed that the positive control and the six target sites all showed fluorescence results, proving that the RT / RPA-CRISPR / Cas12a reagent system combined with the centrifugal chip can realize the parallel detection of the new coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus and parainfluenza type 3 virus, and the entire detection reaction can be completed within 20-30 minutes.

[0059] Embodiment 5:

[0060] Single tube detection of respiratory syncytial virus and sensitivity test

[0061] Respiratory syncytial virus was detected using a single-tube RPA-CRISPR / Cas12a method, which temporarily isolates the amplification reaction and the detection reaction by physical space separation.

[0062] like Figure 5As shown, the entire reaction is carried out in a closed EP tube, the CRISPR / Cas12a detection system is added to the inner wall of the tube cap, and the RPA amplification reagent is added to the bottom of the EP tube. After the RPA amplification is completed, the CRISPR / Cas12a detection system and the RPA amplification product are mixed by centrifugation to perform a detection reaction.

[0063] The RT-RPA amplification system at the bottom of the tube is:

[0064] Reaction Mix 3μL, Reaction Buffer 10μL, dNTPs 1μL, upstream and downstream primers 1μL each, RNA 2μL, MgOAc 2μL, a total of 20μL.

[0065] The CRISPR / Cas12a detection system on the tube cap is:

[0066] LbaCas12a 1μL, CrRNA1μL, FQ Reporter 1μL, 10×NEBuffer 2μL, total 5μL.

[0067] The MgOAc in the RPA system was added last, and the test tube with the CRISPR / Cas12a detection system was immediately covered lightly and placed on a thermostat for incubation at 42°C for 10 minutes to perform the RPA amplification reaction. After the RPA was completed, an instant centrifugation was performed to mix the CRISPR / Cas12a detection system on the tube cap with the RPA amplification product. After centrifugation, the reaction tube was quickly placed on the LightCycler 96 system and reacted at 42°C for 10-15 minutes.

[0068] The single-tube RPA-CRISPR / Cas12a reagent system established in this study can present the test results in a variety of ways, such as real-time fluorescence, endpoint fluorescence, and nucleic acid test strips. In this example, the endpoint fluorescence interpretation method was selected to present the test results, and the sensitivity of the scheme for detecting positive respiratory syncytial virus quality control products was evaluated. The specific process is as follows: Using artificially prepared RNA as a template, EASY Dilution was used for concentration adjustment and gradient dilution, so that the concentration of each group of templates was 10 6 copies / μL, 10 5 copies / μL, 10 4 copies / μL, 10 3 copies / μL, 10 2 copies / μL, 10 1 copies / μL.

[0069] like Figure 6As shown, the PCR tube after the reaction was imaged under a gel imager, and the results showed that the sensitivity of the single-tube RPA-CRISPR / Cas12a reagent system for detecting respiratory syncytial virus quality control products reached 10 copies / μL.

[0070] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. Detection of crRNA of respiratory viruses based on RPA-CRISPR / Cas12a, characterized by: The respiratory viruses include novel coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus and / or parainfluenza virus; the crRNA sequence for detecting novel coronavirus is shown in SEQ ID NO: 1 or SEQ ID NO: 4; the crRNA sequence for detecting influenza A virus is shown in SEQ ID NO: 7; the crRNA sequence for detecting influenza B virus is shown in SEQ ID NO: 10; the crRNA sequence for detecting respiratory syncytial virus is shown in SEQ ID NO: 13; the crRNA sequence for detecting parainfluenza virus is shown in SEQ ID NO:

16.

2. The RPA amplification primer for crRNA amplification of respiratory viruses according to claim 1, characterized in that: The sequences of the RPA amplification primers for amplifying the novel coronavirus are shown in SEQ ID NOs: 2-3 or SEQ ID NOs: 5-6; the sequences of the RPA amplification primers for amplifying influenza A virus are shown in SEQ ID NOs: 8-9; the sequences of the RPA amplification primers for amplifying influenza B virus are shown in SEQ ID NOs: 11-12; the sequences of the RPA amplification primers for amplifying respiratory syncytial virus are shown in SEQ ID NOs: 14-15; and the sequences of the RPA amplification primers for amplifying parainfluenza virus are shown in SEQ ID NOs: 17-18.

3. A kit for detecting respiratory viruses based on RPA-CRISPR / Cas12a, characterized in that: The kit comprises the RPA amplification primers and CRISPR / Cas12a detection system described in claim 2; the CRISPR / Cas12a detection system comprises the crRNA sequence, CRISPR / Cas12a protein and ssDNA reporter fluorescent probe described in claim 1.

4. The kit for detecting respiratory viruses based on RPA-CRISPR / Cas12a according to claim 3, characterized in that: The ssDNA reporter fluorescent probe is a ssDNA labeled with 6-carboxyl fluorescence and a fluorescence quencher.

5. A method for detecting respiratory viruses using the kit according to any one of claims 3-4 for non-disease diagnosis purposes, characterized in that: The following steps are involved: (1) extracting nucleic acid from the sample to be tested; (2) amplifying the nucleic acid in the sample to be tested using RPA amplification primers; (3) After cutting the amplified product using the CRISPR / Cas12a detection system, the fluorescence signal is detected using a fluorescence detector to determine whether the sample contains respiratory viruses.

6. The method for detecting respiratory viruses using a kit according to claim 5, characterized in that: The kit uses a centrifugal microfluidic chip or an EP tube for detection.

7. The method for detecting respiratory viruses using a kit according to claim 5, characterized in that: When the kit uses a centrifugal microfluidic chip, the RPA amplification primer and crRNA sequence are pre-embedded in the chip reaction chamber in the form of freeze-dried powder, the CRISPR / Cas12a detection system is pre-embedded in the independent detection chamber of the chip, the nucleic acid extracted in step (1) is added to the liquid storage tank, and the nucleic acid extracted in step (1) is diverted to the chip reaction chamber for RPA amplification reaction by centrifugation. After the amplification is completed, centrifugation is performed, and the amplification product enters the independent detection chamber of the chip. Finally, the fluorescence signal of the independent detection chamber is detected. When the independent detection chamber emits fluorescence, it indicates that the sample to be tested contains respiratory viruses. When the independent detection chamber system does not emit fluorescence, it indicates that the sample to be tested is not infected with respiratory viruses.

8. The method for detecting respiratory viruses using a kit according to claim 5, characterized in that: When the kit uses an EP tube, the CRISPR / Cas12a detection system is dripped into the inner wall of the EP tube cap, the RPA amplification primer is added to the bottom of the EP tube, and the sample to be tested is added to the bottom of the EP tube. After the amplification reaction is completed, the CRISPR / Cas12a detection system and the RPA amplification product are mixed by centrifugation to perform a detection reaction, and finally the fluorescence signal of the reaction system is detected. When the reaction system emits fluorescence, it indicates that the sample to be tested contains respiratory viruses. When the reaction system does not emit fluorescence, it indicates that the sample to be tested is not infected with respiratory viruses.

9. The method for detecting respiratory viruses using a kit according to claim 5, characterized in that: In the step (2), the concentration of the RPA amplification primer is 10 μM, and the concentration ratio of the upstream and downstream primers is 1:

1.

10. The method for detecting respiratory viruses using a kit according to claim 5, characterized in that: In the step (3) CRISPR / Cas12a detection system, the concentration of the crRNA sequence is 2 μM, the concentration of the ssDNA reporter fluorescent probe is 10 μM, and the concentration of Cas12a is 1 μM.

Citation Information

Cited By

  • Technology for rapidly detecting influenza B virus by RT-RPA-CRISPR / Cas12a one-step method and application thereof

    CN120249562A

  • Kit for visually detecting H5 subtype avian influenza virus based on RPA-CRISPR / Cas12b system and application

    CN120485438A

  • CRISPR / CAS12a-MIRA-based sequence combination for rapidly detecting A flow and application

    CN120555659A

  • RPA-CRISPR / Cas12b technology-based rapid detection method for rice blight germs

    CN120905416A

  • A rapid detection method for rice false smut fungus based on RPA-CRISPR / Cas12b technology

    CN120905416B